Publicis Groupe completed its acquisition of LiveRamp on November 2, 2026. Can shared marketing infrastructure remain neutral when one of the world’s largest advertising groups owns it? For pharmaceutical marketers, media data neutrality is becoming an important consideration alongside patient privacy, audience targeting, and campaign performance. The challenge is determining whether customers can count on fair access, data protection, and meaningful choice.
Table of Contents
- Why Neutral Data Access Became a Merger Condition
- When Agency Ownership Meets Shared Data Infrastructure
- What FTC Safeguards Do and Do Not Guarantee
- How Pharma Marketers Should Test Neutrality and Interoperability
- Conclusion
- FAQ
Why Neutral Data Access Became a Merger Condition
LiveRamp helps organizations connect audiences and measure campaigns without routinely exchanging raw customer records. Its identity resolution and data collaboration tools serve advertisers, publishers, and agencies, including companies that compete with Publicis. Unlike agency-owned advertising inventory, LiveRamp provides infrastructure that many businesses depend on to reach audiences and understand marketing results.
On October 19, 2026, the Federal Trade Commission announced a proposed consent agreement addressing competition concerns surrounding the $2.2 billion acquisition. The FTC alleged that Publicis could use its ownership to disadvantage competing agencies or gain access to confidential customer information. These concerns involve potential competitive harm, not findings that such misuse has already occurred.
For pharmaceutical brands, questions about fair access to shared marketing data have real business implications. Drug manufacturers often work with multiple agencies, publishers, and measurement providers. When those partners depend on the same identity platform, differences in access, pricing, or technical support could affect campaign reach, costs, and performance.
Consequently, platform ownership deserves attention alongside the familiar questions of audience quality, return on investment, and patient privacy.
When Agency Ownership Meets Shared Data Infrastructure
The central issue differs from traditional concerns about agency media buying. In those cases, advertisers may question whether an agency profits from reselling inventory or favors particular media placements. Here, the concern is ownership of technology used by competing advertising businesses.
LiveRamp provides identity matching, partner connectivity, and data collaboration services. Meanwhile, Publicis owns Epsilon, an established identity and audience data business. Combining these capabilities may offer benefits, including faster campaign activation, more connected measurement, and improved use of first-party customer data.
However, integration also creates questions about structural independence. Could competing agencies receive slower support? Might customers face different contractual terms? Could confidential campaign strategies become visible to another company within the same corporate group?
These are questions marketers should examine rather than assume the answers. Publicis has publicly committed to maintaining LiveRamp’s independence, customer choice, and interoperability. Nevertheless, contractual commitments and independent verification remain important.
For pharma advertisers, neutrality extends beyond technical performance. A platform may deliver excellent audience matching while still creating concerns about vendor dependence, information access, or switching costs.
Therefore, marketers should evaluate both what the technology delivers and how the organization controlling it treats competing customers.
What FTC Safeguards Do and Do Not Guarantee
The FTC’s proposed agreement includes several measures intended to protect competition. For five years, Publicis and LiveRamp would be required to provide nondiscriminatory access and support for LiveRamp’s standalone products and services. The proposal also addresses fair pricing, product functionality, interoperability, and customer choice.
Importantly, the proposed conditions require data firewalls designed to prevent Publicis from accessing or using confidential information obtained through LiveRamp’s standalone services. These restrictions are intended to protect competing agencies and their clients.
Independent oversight adds another layer of accountability. Under the proposed agreement, an auditor would review compliance every six months during the first two years and annually during the following three years. Customers could also request certain audits related to their data protection and security rights.
As of November 11, 2026, the FTC proceeding remained pending. The proposed agreement should therefore not be confused with a final, permanent regulatory settlement.
For pharmaceutical advertisers, these safeguards address competition and confidentiality concerns, but they do not replace healthcare privacy obligations. Pharma marketers must also evaluate data independence, patient consent, security safeguards, and compliance with applicable health data regulations.
This distinction is especially important when advertising activity involves sensitive health interests. A privacy-focused platform cannot automatically make every data use appropriate or legally permitted.
As Pharma Marketing Network explains in its article about healthcare tracking pixels, advertisers need to understand what information their technology collects, where that information travels, and who can access it.
How Pharma Marketers Should Test Neutrality and Interoperability
Pharmaceutical marketing teams should begin by asking technology vendors to explain their data governance practices. Who can access audience inputs, campaign plans, match results, and confidential business information? What prevents information from moving between competing business units?
Next, examine the contractual protections. Written agreements should explain access controls, data retention, confidentiality requirements, audit rights, and procedures for resolving disputes.
Interoperability deserves equal attention. Can a pharmaceutical advertiser change agencies without rebuilding its audience strategy? Can independent publishers and measurement providers connect through comparable technical arrangements? Are service levels and support standards consistent across customers?
Furthermore, marketers should test these capabilities instead of relying entirely on vendor presentations. Demonstrations, technical documentation, and independent assessments can reveal practical limitations.
Performance should also be evaluated separately from ownership concerns. Compare audience match quality, reach, measurement accuracy, and reporting capabilities across available providers.
For organizations exploring privacy-focused collaboration, Pharma Marketing Network’s guide to pharma data clean rooms provides additional context on connecting marketing information while limiting exposure of sensitive records.
Finally, involve procurement, legal, privacy, and media teams before renewing major technology agreements. Specialized healthcare advertising partners, including eHealthcare Solutions, can also be asked to explain their technology dependencies and how they manage audience data.
The goal is not to reject platforms simply because an agency holding company owns them. Instead, pharmaceutical marketers should expect clear evidence of fair treatment, reliable safeguards, and the freedom to choose competing partners.
Conclusion
Publicis’s acquisition of LiveRamp makes ownership of shared marketing infrastructure a practical consideration for pharmaceutical advertisers. The FTC’s proposed safeguards address access, confidentiality, and oversight, but marketers still need to evaluate how these protections work in practice.
For pharmaceutical advertisers, fair data access and strong privacy protections are just as important as accurate targeting and reliable campaign measurement.
Ultimately, better technology creates value only when customers can trust how it operates, understand who controls their information, and retain meaningful choices.
FAQ
What does media data neutrality mean?
It means advertisers and agencies can access shared marketing data services on fair terms without improper exposure of confidential information or preferential treatment based on business relationships.
Did the FTC block the Publicis and LiveRamp acquisition?
No. Publicis completed the acquisition on November 2, 2026. The FTC announced a proposed consent agreement containing competition safeguards in October.
Can LiveRamp customers continue working with competing agencies?
Yes. The proposed safeguards are designed to preserve access to LiveRamp’s standalone services regardless of customers’ agency relationships.
Do data clean rooms automatically protect sensitive healthcare information?
No. Clean rooms can reduce unnecessary data exposure, but organizations must still evaluate consent, permitted uses, access controls, security measures, and applicable privacy regulations.
What should pharma marketers review before choosing a data platform?
Start with data access policies, confidentiality protections, audit rights, interoperability, service standards, and the ability to change agencies or technology partners without unnecessary restrictions.
This content is not medical advice. For any health issues, always consult a healthcare professional. In an emergency, call 911 or your local emergency services.












